Treatment of AA Amyloidosis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions

AA Amyloidosis

Interventions

DRUG

nL-SAA1-01

Personalized antisense oligonucleotide

Trial Locations (1)

Mayo Clinic, Rochester

All Listed Sponsors

lead

Nelson Leung, MD

OTHER

NCT06397001 - Treatment of AA Amyloidosis | Biotech Hunter | Biotech Hunter